Intellia Therapeutics (NASDAQ: NTLA) reported Q1 EPS of ($0.81), $0.10 better than the analyst estimate of ($0.91). Revenue for the quarter came in at $15.04 million versus the consensus estimate of $13.51 million.

For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.